Therapeutic uses of furin and its inhibitors: a patent review

Bibliography

• Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11(5):367-83
   PubMed Web of Science ®Google Scholar
• Artenstein AW, Opal SM. Proprotein convertases in health and disease. N Engl J Med 2011;365(26):2507-18
   PubMedGoogle Scholar
• Wan L, Molloy SS, Thomas L, et al. PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization. Cell 1998;94(2):205-16
   PubMedGoogle Scholar
• Dittie AS, Thomas L, Thomas G, et al. Interaction of furin in immature secretory granules from neuroendocrine cells with the AP-1 adaptor complex is modulated by casein kinase II phosphorylation. EMBO J 1997;16(16):4859-70
   PubMedGoogle Scholar
• Roebroek AJ, Umans L, Pauli IG, et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development 1998;125(24):4863-76
   PubMed Web of Science ®Google Scholar
• Malfait AM, Seymour AB, Gao F, et al. A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Ann Rheum Dis 2012;71(6):1042-8
   PubMedGoogle Scholar
• Scamuffa N, Calvo F, Chrétien M, et al. Proprotein convertases: lessons from knockouts. FASEB J 2006;20:1954-63
   PubMedGoogle Scholar
• Creemers JW, Khatib AM. Knock-out mouse models of proprotein convertases: unique functions or redundancy? Front Biosci 2008;172:4960-71
   Google Scholar
• Roebroek AJ, Taylor NA, Louagie E, et al. Limited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem 2004;279(51):53442-50
   PubMed Web of Science ®Google Scholar
• Couture F, D’Anjou F, Day R. On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol Concepts 2011;2(5):421-38
   PubMedGoogle Scholar
• Taylor NA, Van De Ven WJ, Creemers JW. Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J 2003;17(10):1215-27
   PubMedGoogle Scholar
• Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002;3(10):753-66
   PubMed Web of Science ®Google Scholar
• Khatib A-M, Siegfried G, Chrétien M, et al. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 2002;160:1921-35
   PubMed Web of Science ®Google Scholar
• Harris NC, Achen MG. The proteolytic activation of angiogenic and lymphangiogenic growth factors in cancer - its potential relevance for therapeutics and diagnostics. Curr Med Chem 2013. [Epub ahead of print]
   Google Scholar
• Bassi DE, Fu J, Lopez de Cicco R, et al. Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol Carcinog 2005;44(3):151-61
   PubMed Web of Science ®Google Scholar
• Mbikay M, Sirois F, Yao J, et al. Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 1997;75(10):1509-14
   PubMed Web of Science ®Google Scholar
• Cheng M, Watson PH, Paterson JA, et al. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997;71(6):966-71
   PubMedGoogle Scholar
• Bassi DE, Mahloogi H, Al-Saleem L, et al. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 2001;31(4):224-32
   PubMedGoogle Scholar
• D’Anjou F, Routhier S, Perreault JP, et al. Molecular validation of PACE4 as a target in prostate cancer. Transl Oncol 2011;4(3):157-72
   PubMed Web of Science ®Google Scholar
• McColl BK, Paavonen K, Karnezis T, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J 2007;21(4):1088-98
   PubMed Web of Science ®Google Scholar
• Harris NC, Paavonen K, Davydova N, et al. Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer. FASEB J 2011;25(8):2615-25
   PubMedGoogle Scholar
• Bassi DE, Mahloogi H, Lopez De Cicco R, et al. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 2003;162(2):439-47
   PubMedGoogle Scholar
• Page RE, Klein-Szanto AJP, Litwin S, et al. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 2007;29:289-99
   PubMedGoogle Scholar
• Lin H, Ah Kioon MD, Lalou C, et al. Protective role of systemic furin in immune response-induced arthritis. Arthritis Rheum 2012;64(9):2878-86
   PubMedGoogle Scholar
• Dubois CM, Blanchette F, Laprise MH, et al. Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 2001;158(1):305-16
   PubMed Web of Science ®Google Scholar
• Sanjabi S, Zenewicz LA, Kamanaka M, et al. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 2009;9(4):447-53
   PubMed Web of Science ®Google Scholar
• de Visser KE, Kast WM. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 1999;13(8):1188-99
   PubMed Web of Science ®Google Scholar
• Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18(7):816-27
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005;52(1):128-35
   PubMed Web of Science ®Google Scholar
• Pesu M, Watford WT, Wei L, et al. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature 2008;455(7210):246-50
   PubMed Web of Science ®Google Scholar
• Hallenberger S, Bosch V, Angliker H, et al. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992;360(6402):358-61
   PubMed Web of Science ®Google Scholar
• Zambon MC. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 1999;44(Suppl B):3-9
   PubMedGoogle Scholar
• Fugère M, Day R. Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 2005;26(6):294-301
   PubMedGoogle Scholar
• Anderson S, Laskowski M. inventors Novel protein inhibitors of serine proteinases (e.g., furin) derived from turkey ovomucoid third domain patent. WO002055; 1995
   Google Scholar
• Lu W, Zhang W, Molloy SS, et al. Arg15-Lys17-Arg18 turkey ovomucoid third domain inhibits human furin. J Biol Chem 1993;268(20):14583-5
   PubMedGoogle Scholar
• Anderson ED, Thomas L, Hayflick JS, et al. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J Biol Chem 1993;268(33):24887-91
   PubMed Web of Science ®Google Scholar
• Jean F, Stella K, Thomas L, et al. alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci USA 1998;95(13):7293-8
   PubMedGoogle Scholar
• Thomas G, Anderson ED, Thomas L, et al. inventors Methods and reagents for inhibiting furin endoprotease patent. WO016073; 1994
   Google Scholar
• Jean F, Thomas G. inventors Reagents and methods for inhibiting furin protease activity patent. WO051624; 1999
   Google Scholar
• Basak A, Lotfipour F. Modulating furin activity with designed mini-PDX peptides: synthesis and in vitro kinetic evaluation. FEBS Lett 2005;579(21):4813-21
   PubMedGoogle Scholar
• Dufour EK, Denault JB, Hopkins PC, et al. Serpin-like properties of alpha1-antitrypsin Portland towards furin convertase. FEBS Lett 1998;426(1):41-6
   PubMedGoogle Scholar
• Dubois C. inventor Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases patent. US0127396; 2004
   Google Scholar
• Cohen-Solal M, Khatib A-M. inventors Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease patent. WO144517; 2011
   Google Scholar
• Wahl SM, Allen JB, Costa GL, et al. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med 1993;177(1):225-30
   PubMedGoogle Scholar
• Brandes ME, Allen JB, Ogawa Y, et al. Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991;87(3):1108-13
   PubMedGoogle Scholar
• Matsuda S, Matsuda Y, D’Adamio L. BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2. J Biol Chem 2009;284(23):15815-25
   PubMedGoogle Scholar
• D’Adamio L, Shuji M. inventors Effect of bri proteins on abeta production patent. WO138355; 2006
   Google Scholar
• Cameron A, Appel J, Houghten RA, et al. Polyarginines are potent furin inhibitors. J Biol Chem 2000;275(47):36741-9
   PubMed Web of Science ®Google Scholar
• Kacprzak MM, Peinado JR, Than ME, et al. Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine. J Biol Chem 2004;279(35):36788-94
   PubMed Web of Science ®Google Scholar
• Lindberg I, Cameron A, Appel J, et al. inventors Inhibiting furin with polybasic peptides patent. US0087827; 2003
   Google Scholar
• Sarac MS, Cameron A, Lindberg I. The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 2002;70(12):7136-9
   PubMedGoogle Scholar
• Sarac MS, Peinado JR, Leppla SH, et al. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect Immun 2004;72(1):602-5
   PubMed Web of Science ®Google Scholar
• Kibler KV, Miyazato A, Yedavalli VS, et al. Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. J Biol Chem 2004;279(47):49055-63
   PubMedGoogle Scholar
• Karicherla P, Hobden JA. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2009;50(1):256-62
   PubMed Web of Science ®Google Scholar
• Karicherla P, Hobden JA. Nona-D-arginine amide for prophylaxis and treatment of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 2010;35(3):220-4
   PubMed Web of Science ®Google Scholar
• Karicherla P, Aras S, Aiyar A, et al. Nona-D-arginine amide suppresses corneal cytokines in Pseudomonas aeruginosa keratitis. Cornea 2010;29(11):1308-14
   PubMedGoogle Scholar
• Day R, Lebl M, Strongin A. inventors Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens patent. WO023306; 2009
   Google Scholar
• Monnier PP, Tassew NG. inventors Methods for promoting neuron survival, axonal growth and/or regeneration patent. WO3113107; 2013
   Google Scholar
• Tassew NG, Charish J, Seidah NG, et al. SKI-1 and Furin generate multiple RGMa fragments that regulate axonal growth. Dev Cell 2012;22(2):391-402
   PubMedGoogle Scholar
• Stieneke-Grober A, Vey M, Angliker H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992;11(7):2407-14
   PubMed Web of Science ®Google Scholar
• Garten W, Hallenberger S, Ortmann D, et al. Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones. Biochimie 1994;76(3-4):217-25
   PubMed Web of Science ®Google Scholar
• Henrich S, Cameron A, Bourenkov GP, et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 2003;10(7):520-6
   PubMedGoogle Scholar
• Henrich S, Lindberg I, Bode W, et al. Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol 2005;345(2):211-27
   PubMedGoogle Scholar
• Remacle AG, Gawlik K, Golubkov VS, et al. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int J Biochem Cell Biol 2010;42(6):987-95
   PubMed Web of Science ®Google Scholar
• Becker GL, Lu Y, Hardes K, et al. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem 2012;287(26):21992-2003
   PubMed Web of Science ®Google Scholar
• Day PM, Richards R, Buck C, et al. inventors Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection patent. WO084131; 2006
   Google Scholar
• Burd EM. Human papillomavirus and cervical cancer. Clinical microbiology reviews 2003;16(1):1-17
   PubMed Web of Science ®Google Scholar
• Bassi DE, Zhang J, Cenna J, et al. Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis. Neoplasia 2010;12(7):516-26
   PubMedGoogle Scholar
• Kines RC, Thompson CD, Lowy DR, et al. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci USA 2009. 106(48):20458-63
   Google Scholar
• Ferguson MW, Brunner G. inventors Use of furin “convertase” inhibitors in the treatment of fibrosis and scarring patent. WO009113; 2004
   Google Scholar
• McColl B, Stacker S, Achen M. inventors Method for inhibiting angiogenesis and/or lymphangiogenesis patent. WO112971; 2005
   Google Scholar
• Smith RE. inventor Furin inhibitors patent. WO046781; 2007
   Google Scholar
• Steinmetzer T, Becker G, Garten W. inventors N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic patent. WO048941; 2010
   Google Scholar
• Kwiatkowska A, Couture F, Levesque C, et al. Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem 2014;57(1):98-109
   PubMedGoogle Scholar
• Becker GL, Sielaff F, Than ME, et al. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 2010;53(3):1067-75
   PubMedGoogle Scholar
• Dahms SO, Hardes K, Becker GL, et al. X-ray structures of human furin in complex with competitive inhibitors. ACS Chem Biol 2014;9(5):1113-18
   PubMedGoogle Scholar
• Day R, Neugebauer WA, Dory YL. inventors Stable peptide-based furin inhibitors patent. WO029182; 2013
   Google Scholar
• Gagnon H, Beauchemin S, Kwiatkowska A, et al. Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin. J Med Chem 2014;57(1):29-41
   PubMedGoogle Scholar
• Strongin A, Pellecchia M, Barile E. inventors Inhibitors of furin and other pro-protein convertases patent. WO138666; 2013
   Google Scholar
• Nemunaitis JJ, Senzer N, Maples PB, et al. inventors Furin-knockdown and gm-csf-augmented (fang) cancer vaccine patent. WO079077; 2011
   Google Scholar
• Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 2001;10(50):52-60
   Google Scholar
• Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6(7):506-20
   PubMed Web of Science ®Google Scholar
• Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136(10):3916-20
   PubMed Web of Science ®Google Scholar
• Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8(5):369-80
   PubMed Web of Science ®Google Scholar
• Senzer N, Barve M, Kuhn J, et al. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther 2012;20(3):679-86
   PubMed Web of Science ®Google Scholar
• Senzer N, Barve M, Nemunaitis J, et al. Long term follow up: phase i trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANG™) in advanced cancer. J Vaccines Vaccin 2013;4:209
   Google Scholar
• Binley JM, Sanders RW, Master A, et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2002;76(6):2606-16
   PubMed Web of Science ®Google Scholar
• Rodenhuis-Zybert IA, Wilschut J, Smit JM. Partial maturation: an immune-evasion strategy of dengue virus? Trends Microbiol 2011;19(5):248-54
   PubMedGoogle Scholar
• Neumann G, Feldmann H, Watanabe S, et al. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 2002;76(1):406-10
   PubMed Web of Science ®Google Scholar
• Fuchs SM, Raines RT. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004;43(9):2438-44
   PubMed Web of Science ®Google Scholar
• Garten W, Stieneke A, Shaw E, et al. Inhibition of proteolytic activation of influenza virus hemagglutinin by specific peptidyl chloroalkyl ketones. Virology 1989;172(1):25-31
   PubMed Web of Science ®Google Scholar
• Craik DJ, Fairlie DP, Liras S, et al. The future of peptide-based drugs. Chem Biol Drug Des 2013;81(1):136-47
   PubMed Web of Science ®Google Scholar
• Watanabe M, Hirano A, Stenglein S, et al. Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus. J Virol 1995;69(5):3206-10
   PubMed Web of Science ®Google Scholar
• Levesque C, Fugere M, Kwiatkowska A, et al. The Multi-leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J Med Chem 2012;55(23):10501
   PubMedGoogle Scholar
• Fugere M, Limperis PC, Beaulieu-Audy V, et al. Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem 2002;277(10):7648-56
   PubMed Web of Science ®Google Scholar